Results 121 to 130 of about 19,808 (220)

Focal Spot, Spring 1988 [PDF]

, 1988
https://digitalcommons.wustl.edu/focal_spot_archives/1048/thumbnail ...

core   +1 more source

Establishing a robust radioligand therapy program: A practical approach for North American centers

Cancer Medicine
Radioligand therapy (RLT) is a targeted approach to treating cancer that has been shown to be safe and effective in a variety of disease states, including gastroenteropancreatic neuroendocrine tumors, lymphoma, and most recently, advanced prostate cancer.
Erik S. Mittra, Rebecca K. S. Wong, Celeste Winters, Adam Brown, Shondra Murley, Hagen Kennecke   +5 more
doaj   +1 more source

Actinium-225-PSMA-617 treatment in a patient with advanced prostate cancer causes secondary myelofibrosis: a case report and literature review

Frontiers in Medicine
Advanced prostate cancer (PCa) is still an incurable disease. Still, the field of PSMA-targeted radioligand therapy is developing rapidly and is playing an increasingly important role in the treatment of advanced Pca in the future.
Ziye Wang, Wen Tang, Wen Tang, Mingwen Liu, Zhifei Xie, Yi Li, Jiang Du, Tao Wu   +7 more
doaj   +1 more source

¹⁷⁷Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer

Tidsskrift for Den norske legeforening
Treatment of castration-resistant metastatic prostate cancer with [¹⁷⁷Lu]PSMA radioligand.A man in his seventies with metastatic prostate cancer received castration therapy for four years, developing castration-resistant disease. PET/CT with [⁶⁸Ga]PSMA-11 showed high uptake in metastatic lymph nodes. The patient received 7.4 GBq [¹⁷⁷Lu]PSMA-I&T (Curium,
Sundset, Rune, Haugnes, Hege Sagstuen, Perez, Alexander, Engelsen, Ola, Fosseide, Ida H.H., Castillejo, Miguel J., Bogsrud, Trond Velde   +6 more
openaire   +2 more sources

Research priorities in limb and task-specific dystonias [PDF]

, 2017
Altenmüller, Eckart, Alter, Katharine, Alterman, Ron L, Chen, Robert, Frucht, Steven, Furuya, Shinichi, Hallett, Mark, Jankovic, Joseph, Jinnah, H.A., Kimberley, Teresa J, Lungu, Codrin, Perlmutter, Joel S, Prudente, Cecilia N, Richardson, Sarah Pirio   +13 more
core   +2 more sources

RECIP 1.0 + PSA for response assessment in mCRPC patients treated with 225Ac / 177Lu PSMA combination therapy

EJNMMI Research
Background Targeted alpha therapy (TAT) with 225Ac has shown promising results in metastatic castration-resistant prostate cancer (mCRPC) patients pre-treated with [177Lu]Lu-PSMA radioligand therapy (RLT).
Gabriel T. Sheikh, Astrid Delker, Mathias J. Zacherl, Adrien Holzgreve, Sarah L. Takayama Fouladgar, Marcus Unterrainer, Johannes Rübenthaler, Jozefina Casuscelli, Andrei Gafita, Lena M. Unterrainer   +9 more
doaj   +1 more source

Implementation of a lifestyle‐based clinical pathway in daily clinical practice in men undergoing androgen deprivation therapy for prostate cancer [PDF]

, 2019
Bruggeman, Anniek, Bultijnck, Renée, De Muynck, Martine, Decaestecker, Karel, Deforche, Benedicte, Fonteyne, Valerie, Lumen, Nicolaas, Mortier, Stefanie, Ost, Piet, Raes, Anneleen, Rammant, Elke, Van Ruymbeke, Barbara   +11 more
core   +1 more source

Challenges and Opportunities in Radioligand Therapy. [PDF]

J Nucl Med Technol
Currie GM, Bailey DL.
europepmc   +1 more source

Radioligand Therapy in Meningiomas: Today's Evidence, Tomorrow's Possibilities. [PDF]

Cancers (Basel)
Sipka G, Apro K, Farkas I, Bakos A, Dobi A, Hideghety K, Pavics L, Dosa S, Radics B, Balazsfi M, Barzo P, Szolikova M, Besenyi Z.   +12 more
europepmc   +1 more source

The impact of radioligand therapy on prognosis in patients with lung neuroendocrine tumors. [PDF]

Front Endocrinol (Lausanne)
Jóźwik-Plebanek K, Saracyn M, Durma AD, Kołodziej M, Mądra W, Dziuk M, Janiak K, Balcerska Z, Gniadek-Olejniczak K, Kamiński G.   +9 more
europepmc   +1 more source